Body Composition (DEXA, Visceral Fat)

Navigation & Literature

• Parent Silo: 03 - Diagnostics & Quantified Self MOC
• Literature Dossier: Body Composition (DEXA, Visceral Fat) - References

---

1. Reference Range Comparison (Standard Clinical vs. Longevity Optimal)

DEXA Body Composition Metric	Standard Clinical / Sarcopenia Cutoff	Longevity / Functional Optimal (Top 10%)	Primary Unit	Physiological & Prognostic Role
Visceral Adipose Tissue (VAT) Mass / Area	$<500\text{ g}$ (Area $<100{\text{ cm}}^2$)	$<100–250\text{ g}$ (Area $<30–50{\text{ cm}}^2$; Vol $<250{\text{ cm}}^3$)	$\text{g}$ (${\text{cm}}^2$)	Intra-abdominal omental/mesenteric fat draining directly into portal vein
Appendicular Lean Mass Index (ALMI)	$>7.0{\text{ kg/m}}^2$ (M) / $>5.5{\text{ kg/m}}^2$ (F) (EWGSOP2 sarcopenia cutoff)	$>9.0–10.2{\text{ kg/m}}^2$ (M) / $>6.8–7.6{\text{ kg/m}}^2$ (F) (> 75\text{th–90th %ile})	${\text{kg/m}}^2$	$\text{Arm + Leg Lean Mass (kg)}/{\text{Height (m)}}^2$; primary skeletal muscle functional reserve
Fat Mass Index (FMI)	$3.0–6.0{\text{ kg/m}}^2$ (M) / $5.0–9.0{\text{ kg/m}}^2$ (F)	$2.5–4.5{\text{ kg/m}}^2$ (M) / $4.0–6.5{\text{ kg/m}}^2$ (F)	${\text{kg/m}}^2$	$\text{Total Fat Mass (kg)}/{\text{Height (m)}}^2$ (superior to BMI by separating fat from muscle)
Total Body Fat Percentage	$15–25\%$ (M) / $22–32\%$ (F)	$10–15\%$ (M) / $18–23\%$ (F)	$\%$	Total adiposity (avoid chronic $<7\%$ in men or $<14\%$ in women due to endocrine suppression)
Android : Gynoid (A/G) Fat Ratio	$<1.0$	$<0.80$ (M) / $<0.65$ (F)	$\text{Ratio}$	Central truncal vs. gluteofemoral subcutaneous fat distribution
Bone Mineral Density (BMD T-Score / Z-Score)	$\text{T-score}>-1.0\text{ SD}$ ($-1.0\text{ to }-2.5$ osteopenia)	\text{T-score & Z-score} \ge +1.0\text{ SD}	$\text{SD}$	Trabecular (L1–L4 spine) and cortical (femoral neck/total hip) fracture resilience

DEXA Pre-Scan Standardization Protocol

Because DEXA calculates Lean Soft Tissue Mass from X-ray attenuation of water + protein + glycogen ($1\text{ g}$ of muscle glycogen binds $3–4\text{ g}$ of intracellular water), a high-carbohydrate refeed, creatine loading, or pre-scan hydration shift can artificially inflate reported “lean mass” by $1.0–2.5\text{ kg}$ within 24 hours. Always perform DEXA scans morning fasted, post-void, normohydrated, 24h after last resistance workout, and on the exact same scanner manufacturer/software (GE Lunar vs. Hologic differ by ~2–4% in BF%).

---

2. Physiological Significance & Hazard Curves

Why BMI Fails & Visceral Adipose Tissue (VAT) Drives Inflammaging

Body Mass Index ($\text{BMI}={\text{kg/m}}^2$) fails in two lethal directions: (1) It misclassifies muscular athletes ($\text{ALMI}>9.5{\text{ kg/m}}^2$, $\text{BF}=11\%$) as “overweight”; and (2) It misses “TOFI” (Thin Outside, Fat Inside / Normal-Weight Central Obesity)—individuals with a “normal” BMI of $22–24{\text{ kg/m}}^2$ who suffer from sarcopenic obesity (low ALMI + high intra-abdominal VAT $>500\text{ g}$).

• The Portal Vein Hypothesis & Adipokine Storm: Unlike benign gluteofemoral subcutaneous adipose tissue (which acts as a protective “metabolic sink” storing free fatty acids and secreting insulin-sensitizing adiponectin), Visceral Adipose Tissue (VAT) is densely innervated by ${\beta }_3$-adrenergic receptors, resistant to insulin’s anti-lipolytic action, and infiltrated by pro-inflammatory M1 macrophages. VAT releases free fatty acids, IL-6, TNF-$\alpha$, PAI-1, and resistin directly into the portal vein, flooding the liver to drive hepatic insulin resistance, VLDL/ApoB overproduction, and systemic endothelial inflammation.
• Mortality Hazard: In large DEXA and CT cohorts, every $500\text{ g}$ (or $50{\text{ cm}}^2$) increase in VAT independently increases all-cause mortality ($\text{HR }1.35–1.72$) and cardiometabolic risk by $2\times \text{ to }4\times$, even among normal-BMI adults.

Appendicular Lean Mass Index (ALMI) & The “Centenarian Decathlon” Muscle Reserve

Skeletal muscle is the body’s largest organ for postprandial glucose disposal (~80% of insulin-stimulated glucose uptake) and its primary amino acid reservoir during critical illness or trauma.

• Age-Related Sarcopenia Trajectory: After age 35–40, sedentary humans lose $0.8–1.0\%$ of muscle mass per year and $2.5–3.5\%$ of muscle power (Type IIa/IIx fast-twitch fibers) per year, accelerating sharply during hospital bedrest or after age 65.
• Survival Protection: To remain above the clinical sarcopenia disability threshold ($\text{ALMI}<7.0{\text{ kg/m}}^2$ in men, $<5.5{\text{ kg/m}}^2$ in women) at age 85–90, an individual in their 30s–50s must build and maintain an ALMI in the $>85\text{th–90th percentile}$ ($>9.2{\text{ kg/m}}^2$ for men, $>7.0{\text{ kg/m}}^2$ for women) today. In NHANES DEXA mortality analyses (Srikanthan & Karlamangla; Abramowitz et al.), individuals in the highest quartile of appendicular muscle mass Index had a 20–35% lower risk of all-cause mortality ($\text{HR }0.65–0.80$).

Bone Mineral Density (BMD): The Mechanical & Endocrine Bank Account

Hip fractures after age 65 carry a 1-year all-cause mortality rate of 20–30% due to immobilization, venous thromboembolism, pneumonia, and rapid catabolic muscle loss. DEXA quantifies Areal BMD (${\text{g/cm}}^2$) at the lumbar spine (L1–L4, rich in metabolically active trabecular bone; optionally enhanced with Trabecular Bone Score [TBS] for microarchitecture) and femoral neck/total hip (cortical bone).

---

3. Root Causes of VAT Accumulation, Sarcopenia & Osteopenia

• Visceral Fat Drivers: Hypercortisolemia (visceral adipocytes express $4\times$ higher glucocorticoid receptor density and $11\beta \text{-HSD1}$ than subcutaneous adipocytes; see HPA Axis & Cortisol Modulation), hyperinsulinemia, dietary liquid fructose, sleep curtailment, and age-related declines in pulsatile growth hormone (GH) and testosterone/estradiol (Endocrine & Hormone Panel).
• Anabolic Resistance & Sarcopenia: Sedentary behavior, inadequate per-meal dietary protein/leucine ($<3.0\text{ g}$ leucine/meal fails to trigger mTORC1 ribosomal translation in older muscle), chronic inflammation, and GLP-1 agonist therapy without concurrent heavy resistance training and high protein intake ($1.6–2.2\text{ g/kg/day}$).
• Osteopenia / Low BMD: Absence of high-strain axial mechanical impact (Wolff’s Law), low estradiol ($<20\text{ pg/mL}$ in men or post-menopause), Vitamin D3 / K2 insufficiency, or chronic proton pump inhibitor / glucocorticoid use.

---

4. Actionable Interventions

Foundational Protocols (01 - Foundations)

• Mechanical Loading for ALMI & Bone Density (LIFTMOR Protocol):
  • Execute progressive overload compound Resistance Training & Hypertrophy ($3–4\times \text{/week}$ at $75–85\%\text{ 1RM}$: deadlifts, squats, overhead press, loaded carries) paired with high-impact plyometrics/jumping (validated in the LIFTMOR RCT to actively increase lumbar spine and femoral neck BMD by $+2.9\%$ even in postmenopausal osteopenia/osteoporosis).
  • Target $1.6–2.2\text{ g/kg}$ of ideal body weight in dietary protein/day, distributed in $35–50\text{ g}$ boluses ($>3.5\text{ g}$ leucine) to overcome anabolic resistance per Macronutrient & Micronutrient Optimization.
• Selective Visceral Fat Oxidation: Combine Zone 2 & VO2 Max plus high-intensity intervals (which release catecholamines that selectively bind visceral ${\beta }_3$-adrenergic receptors) with Time-Restricted Feeding & Fasting.

Molecular & Pharmacological Interventions (02 - Compounds & Molecules)

• Selective Visceral Adipose Lipolysis Peptides:
  • Tesamorelin ($1–2\text{ mg/day}$ SC before bed): FDA-approved 44-amino-acid GHRH analog that restores physiological pulsatile GH secretion and selectively reduces Visceral Adipose Tissue (VAT) by 15–20% over 26 weeks without reducing subcutaneous fat or impairing glucose homeostasis via GH Secretagogues (Ipamorelin, CJC-1295, Tesamorelin).
  • Retatrutide / Tirzepatide (Triple GLP-1/GIP/Glucagon or Dual Agonists) & MOTS-c: Glucagon receptor co-agonism drives hepatic and visceral fat oxidation ($>80\%$ resolution of liver/visceral fat), MUST be paired with resistance training + high protein + creatine to preserve ALMI via Mitochondrial & Metabolic Peptides (MOTS-c, SS-31, GLP-1).
• Anabolic & Osteogenic Cofactor Stack:
  • Creatine Monohydrate ($5\text{ g/day}$): Increases intracellular phosphocreatine, cell volumization, satellite cell myogenesis, and bone mineral density when paired with resistance training (Creatine & Phosphocreatine System).
  • Vitamin D3 ($5,000\text{ IU}$) + Vitamin K2 (MK-7 $180\mu \text{g}$ / MK-4 $1.5–45\text{ mg}$) + Magnesium + Boron ($3–6\text{ mg}$): Carboxylates osteocalcin and Matrix Gla Protein to lock calcium into bone trabeculae while keeping it out of arterial walls (Vitamin D3, K2 & Calcium Homeostasis).
  • Essential Amino Acids (EAAs $10–15\text{ g}$ / HMB $3\text{ g}$): Prevent lean mass catabolism during caloric deficits or fasting (Amino Acids & Precursors).

---

5. Key Scientific Evidence Summary

• Srikanthan & Karlamangla (2014, American Journal of Medicine) & Abramowitz et al. (2018, PLoS ONE): NHANES cohorts ($n=3,659$ to $11,687$) proving Appendicular Muscle Mass Index (ALMI) independently predicts lower all-cause mortality, and revealing that BMI masks high-mortality low-muscle/high-visceral-fat phenotypes.
• Kuk et al. (2006, Obesity): Demonstrated via direct imaging that Visceral Fat is a strong, independent predictor of all-cause mortality ($\text{OR }1.83$ per SD), whereas subcutaneous and peripheral fat are non-hazardous or protective.
• Stanley et al. (2014, Lancet HIV / NEJM 2009): Randomized placebo-controlled trials proving Tesamorelin reduces visceral adipose tissue area by $-15.2\%\text{ to }-18\%$ ($-24\text{ to }-34{\text{ cm}}^2$, $p<0.0001$) and reduces hepatic fat fraction by $-37\%$.
• Watson et al. (2018, Journal of Bone and Mineral Research — LIFTMOR Trial): Proved 8 months of twice-weekly, 30-minute High-Intensity Resistance and Impact Training (HiRIT at $>80–85\%\text{ 1RM}$) increases lumbar spine BMD by $+2.9\%$ ($p<0.001$) and femoral neck BMD by $+0.3\%$ vs. $-1.2\%$ loss in controls.

See full bibliographic details and quantitative effect sizes in Body Composition (DEXA, Visceral Fat) - References.